Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wade

Showing results (461-470 of 500) with videos related to

Pageof 50
Sort By:
British Journal of Pharmacology|June 8, 2012
Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonistP R Wade, J M Palmer, S McKenney, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Physical Review Letters|July 15, 2003
Modification of the current profile in high-performance plasmas using off-axis electron-cyclotron-current drive in DIII-DM Murakami, M R Wade, C M Greenfield, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Nature Communications|February 22, 2023
Phosphoproteomics reveals rewiring of the insulin signaling network and multi-nodal defects in insulin resistanceDaniel J Fazakerley, Julian van Gerwen, Kristen C Cooke, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Nature Medicine|December 28, 2010
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectinWilliam L Holland, Russell A Miller, Zhao V Wang, et al.
Science (New York, N.Y.)|February 28, 2019
Animal cultures matter for conservationPhilippa Brakes, Sasha R X Dall, Lucy M Aplin, et al.
Molecular Ecology|June 20, 2015
Geographic and temporal dynamics of a global radiation and diversification in the killer whalePhillip A Morin, Kim M Parsons, Frederick I Archer, et al.
Neuropharmacology|July 8, 2008
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areasKenneth W Perry, Julie F Falcone, Matthew J Fell, et al.
Pageof 50

Showing results (461-470 of 500) with videos related to

Sort By:
Pageof 50
British Journal of Pharmacology|June 8, 2012
Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonistP R Wade, J M Palmer, S McKenney, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Physical Review Letters|July 15, 2003
Modification of the current profile in high-performance plasmas using off-axis electron-cyclotron-current drive in DIII-DM Murakami, M R Wade, C M Greenfield, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Nature Communications|February 22, 2023
Phosphoproteomics reveals rewiring of the insulin signaling network and multi-nodal defects in insulin resistanceDaniel J Fazakerley, Julian van Gerwen, Kristen C Cooke, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Nature Medicine|December 28, 2010
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectinWilliam L Holland, Russell A Miller, Zhao V Wang, et al.
Science (New York, N.Y.)|February 28, 2019
Animal cultures matter for conservationPhilippa Brakes, Sasha R X Dall, Lucy M Aplin, et al.
Molecular Ecology|June 20, 2015
Geographic and temporal dynamics of a global radiation and diversification in the killer whalePhillip A Morin, Kim M Parsons, Frederick I Archer, et al.
Neuropharmacology|July 8, 2008
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areasKenneth W Perry, Julie F Falcone, Matthew J Fell, et al.
Pageof 50